Private Trust Co. NA increased its holdings in shares of iShares NASDAQ Biotechnology Index (NASDAQ:IBB) by 220.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,538 shares of the financial services provider’s stock after acquiring an additional 3,120 shares during the period. Private Trust Co. NA’s holdings in iShares NASDAQ Biotechnology Index were worth $484,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in IBB. CHURCHILL MANAGEMENT Corp boosted its position in iShares NASDAQ Biotechnology Index by 223.2% in the 4th quarter. CHURCHILL MANAGEMENT Corp now owns 1,801,330 shares of the financial services provider’s stock valued at $192,328,000 after buying an additional 1,244,066 shares during the last quarter. Clal Insurance Enterprises Holdings Ltd boosted its position in iShares NASDAQ Biotechnology Index by 175.5% in the 3rd quarter. Clal Insurance Enterprises Holdings Ltd now owns 635,875 shares of the financial services provider’s stock valued at $212,132,000 after buying an additional 405,091 shares during the last quarter. Quantitative Investment Management LLC bought a new position in iShares NASDAQ Biotechnology Index in the 2nd quarter valued at $103,504,000. Tudor Investment Corp ET AL bought a new position in iShares NASDAQ Biotechnology Index in the 2nd quarter valued at $24,186,000. Finally, Archford Capital Strategies LLC boosted its position in iShares NASDAQ Biotechnology Index by 1,393.5% in the 2nd quarter. Archford Capital Strategies LLC now owns 64,087 shares of the financial services provider’s stock valued at $1,085,000 after buying an additional 59,796 shares during the last quarter. Institutional investors and hedge funds own 21.23% of the company’s stock.
iShares NASDAQ Biotechnology Index (NASDAQ:IBB) opened at $110.60 on Wednesday. iShares NASDAQ Biotechnology Index has a 12-month low of $88.96 and a 12-month high of $114.17.
The company also recently disclosed a quarterly dividend, which was paid on Thursday, December 28th. Shareholders of record on Friday, December 22nd were given a $0.125 dividend. This represents a $0.50 dividend on an annualized basis and a yield of 0.45%. This is a positive change from iShares NASDAQ Biotechnology Index’s previous quarterly dividend of $0.04. The ex-dividend date of this dividend was Thursday, December 21st.
COPYRIGHT VIOLATION NOTICE: This story was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another domain, it was illegally copied and reposted in violation of US & international copyright law. The legal version of this story can be read at https://www.dispatchtribunal.com/2018/01/17/ishares-nasdaq-biotechnology-index-ibb-shares-bought-by-private-trust-co-na.html.
iShares NASDAQ Biotechnology Index Company Profile
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
Receive News & Ratings for iShares NASDAQ Biotechnology Index Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares NASDAQ Biotechnology Index and related companies with MarketBeat.com's FREE daily email newsletter.